Pantoprazol Aptapharma (Pantoprazole)

Pantoprazol Aptapharma is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Erosive oesophagitis: accelerates mucosal healing and prevents disease progression.
• Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumours.
• Peptic ulcer disease (duodenal and gastric ulcers): supports ulcer healing and reduces recurrence risk.

• Pantoprazole selectively and irreversibly binds to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By inhibiting this final step of acid production, it markedly lowers gastric acidity, allowing damaged mucosa to heal and reducing symptoms associated with excess acid.

Pantoprazol Aptapharma may cause adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea or abdominal discomfort.
• Flatulence or bloating.
• Constipation: occasional.
• Dry mouth.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing.
• Clostridioides difficile‑associated colitis: persistent watery diarrhoea.
• Acute interstitial nephritis: sudden rise in serum creatinine.
• Hepatic dysfunction: elevated transaminases.
• Osteoporotic fractures: increased risk with long‑term use.
• Hypomagnesaemia: muscle cramps, arrhythmia, seizures.

When prescribing Pantoprazol Aptapharma, clinicians should consider several safety aspects:

• Renal impairment: dose adjustment may be required.
• Hepatic impairment: monitor liver function tests.
• Long‑term therapy: assess bone health and magnesium levels periodically.
• Concomitant use with clopidogrel: evaluate bleeding risk.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Aptapharma can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect, may increase cardiovascular events.
• Atazanavir or other protease inhibitors: markedly decreased antiviral exposure.
• Methotrexate (high dose): increased serum concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of INR, monitor coagulation.
• Digoxin: slight increase in serum levels, observe for toxicity.
• Diazepam: enhanced sedation, adjust dose if needed.